WhiteLab Genomics · May 2026
Company reported ~50x higher DNA enrichment in the brain versus AAV9 after IV injection in mice, with undetectable liver signal, and positioned the ALFRED platform for neurological genomic medicine.
Unleashing the potential of DNA and RNA based therapies using AI
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
WhiteLab Genomics is a Paris-area TechBio company founded in 2019 that uses its ALFRED AI platform to design and optimize genomic medicine components—especially viral and non-viral vectors, payloads, and bioproduction workflows—through a co-development model with pharma, biotech, and academic partners.
Primary product
ALFRED AI platform for genomic medicine design and optimization
Founded
2019
Headquarters
Évry-Courcouronnes, Île-de-France, France
Team size
11-50
Work style
Hybrid
Industry
Biotechnology Research
Sub-industry
TechBio / AI for genomic medicine
Offices
Future4Care, 8 Rue Jean Antoine de Baïf, 75013 Paris, France
Bayer Co.Lab, 238 Main St, Cambridge, MA 02142, USA
1, Place Ville Marie, Montréal, Québec H3B 4M7, Canada
4 rue Pierre Fontaine, 91000 Évry, France
Business model
B2B platform partnerships
co-development with pharma, biotech, and academic labs
R&D collaboration services
milestone-based licensing / partnering
Funding
Stage
Series A
Total raised
$10.6M
Latest round
Incubator/Accelerator - II · Nov 2023
Nov 2023 · Health Industries and Technologies Accelerator
Sep 2022 · Debiopharm Innovation Fund / Omnes Capital
Mar 2022 · Y Combinator
Sep 2020 · BPI France / Bpifrance
Mar 2020 · Bpifrance
Mar 2020 · Wilco
Feb 2020
Sep 2019 · EIT Health
People & investors
Leadership
CEO and Co-Founder
Chief Scientific Officer and Co-Founder
Co-Founder and Chief Operating Officer
Chief Financial & Corporate Development Officer
Global Head of Business Development & Licensing
Head of Partnerships
Head of Computational Biology
Director of Drug Design
Head of Scientific Project Management
Work & culture
The company emphasizes CARE, TEAMWORK, COMMUNICATION, CAN-DO, and EXCELLENCE, and repeatedly describes its culture as human-first, collaborative, and transversal.
Work style
Hybrid
Compensation
No public salary bands or compensation details were found.
Benefits
Flexible hybrid work policy
Comprehensive health coverage
Learning & development
Scientific trainings
Project management workshops
Lunch & Learn sessions
Opportunities to attend global industry events
International work environment
Diverse team across 20+ nationalities
Product & market
Pricing
Not publicly disclosed; public materials describe multi-year development partnerships and collaborations, with value likely coming from upfront fees, milestones, and/or royalties rather than direct software pricing.
Differentiators
- —End-to-end workflow from target discovery to in vivo validation
- —Modality-agnostic platform across AAV, lentivirus, LNPs, and payloads
- —Rational design using AI plus structural biology and curated datasets
- —Wet-lab validation loop to de-risk computational predictions
- —Focus on delivery systems and manufacturability, not just discovery
- —French-American footprint with offices in Paris, Boston, and Montréal
Technology
ALFRED AI
protein language models
deep learning
generative AI
machine learning
physics-based algorithms
biostatistics
graph knowledge technology
structural biology
reinforcement learning
LLMs
RAG
knowledge graphs
multi-omics
Customers
Sanofi
Cytiva
Debiopharm
Siren Biotechnology
Carbon Biosciences
UMass Chan Medical School
Institut Imagine
Généthon
INSERM
Institut de la Vision
Nantes University / TaRGeT Laboratory
Competitors
BenevolentAI
Dyno Therapeutics
AskBio
AQEMIA
Terray Therapeutics
Partex
ReviveMed
Variational AI
64x Bio
Senti Bio
Scale & contact
Estimated revenue
$1M-$10M
Estimated monthly visits
3.4K
Traffic estimate as of Jul 2026
Latest news
WhiteLab Genomics · Nov 2025
WhiteLab and UMass Chan said they would use ALFRED for synthetic promoter design to fine-tune AAV payload expression in neurological diseases linked to mitochondrial dysfunction.
WhiteLab Genomics · Jun 2025
WhiteLab and Carbon Biosciences said they would combine ALFRED with Carbon's PAVE vectors to create new gene-therapy opportunities beyond AAV across underserved indications.
WhiteLab Genomics · Apr 2025
The company announced four research presentations covering retinal AAV engineering, a synthetic peptide library, peptide-design hit rates, and an LLM/RAG/knowledge-graph downstream processing tool called OLIVIA.
WhiteLab Genomics · Sep 2024
The collaboration aimed to identify cancer-specific receptors and binding agents for lipid nanoparticles to improve targeted delivery in oncology.
Jobs and careers at WhiteLab Genomics
0 jobs at WhiteLab Genomics
No open positions
Check back later for new openings